DE602005018914D1 - Annexin zur prävention von der ruptur des plaques - Google Patents

Annexin zur prävention von der ruptur des plaques

Info

Publication number
DE602005018914D1
DE602005018914D1 DE602005018914T DE602005018914T DE602005018914D1 DE 602005018914 D1 DE602005018914 D1 DE 602005018914D1 DE 602005018914 T DE602005018914 T DE 602005018914T DE 602005018914 T DE602005018914 T DE 602005018914T DE 602005018914 D1 DE602005018914 D1 DE 602005018914D1
Authority
DE
Germany
Prior art keywords
annexin
binding
rupture
preventing
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005018914T
Other languages
English (en)
Inventor
Anna Frostegard
Johan Frostegard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athera Biotechnologies AB
Original Assignee
Athera Biotechnologies AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies AB filed Critical Athera Biotechnologies AB
Publication of DE602005018914D1 publication Critical patent/DE602005018914D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Escalators And Moving Walkways (AREA)
  • Cosmetics (AREA)
DE602005018914T 2004-04-15 2005-04-15 Annexin zur prävention von der ruptur des plaques Active DE602005018914D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138504P 2004-04-15 2004-04-15
PCT/GB2005/001451 WO2005099744A1 (en) 2004-04-15 2005-04-15 Annexin v for preventing atherothrombois and plaque rupture

Publications (1)

Publication Number Publication Date
DE602005018914D1 true DE602005018914D1 (de) 2010-03-04

Family

ID=34966761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018914T Active DE602005018914D1 (de) 2004-04-15 2005-04-15 Annexin zur prävention von der ruptur des plaques

Country Status (15)

Country Link
US (1) US20080044404A1 (de)
EP (1) EP1755642B1 (de)
JP (2) JP2007532617A (de)
CN (1) CN1997385B (de)
AT (1) ATE454898T1 (de)
AU (1) AU2005232436C1 (de)
CA (1) CA2563408C (de)
CY (1) CY1109959T1 (de)
DE (1) DE602005018914D1 (de)
DK (1) DK1755642T3 (de)
ES (1) ES2356364T3 (de)
PL (1) PL1755642T3 (de)
PT (1) PT1755642E (de)
SI (1) SI1755642T1 (de)
WO (1) WO2005099744A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
JP2011506590A (ja) 2007-12-18 2011-03-03 アセラ・バイオテクノロジーズ・アーベー 血管疾患を治療するための化合物および方法
HUE035034T2 (en) * 2008-02-22 2018-05-02 Annexin Pharmaceuticals Ab Compounds and methods for preventing or treating restenosis
EP2350112A4 (de) 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Ortsspezifische n-terminus-proteinmodifikationen und konjugatbildung
US9192649B2 (en) 2008-10-17 2015-11-24 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
WO2010069605A2 (en) * 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
WO2012136819A1 (en) 2011-04-05 2012-10-11 Athera Biotechnologies Ab Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
WO2013109144A1 (en) * 2012-01-18 2013-07-25 Stichting Katholieke Universiteit Annexin a5 snp in atherosclerosis
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
CN105327042A (zh) * 2015-12-16 2016-02-17 刘爱玲 一种治疗颈动脉斑块的中药药膏及制备方法
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
EP4355765A2 (de) 2021-06-14 2024-04-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Mutierte annexin-a5-polypeptide und verwendungen davon für therapeutische zwecke
WO2023143463A1 (en) * 2022-01-30 2023-08-03 Nanjing Reju Therapeutics , Inc. Fusion protein and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
WO1996015152A1 (fr) * 1994-11-11 1996-05-23 International Reagents Corporation Anticorps monoclonal antiannexine-v, procede pour produire cet anticorps, et utilisation de cet anticorps
WO1999002992A1 (en) * 1997-07-11 1999-01-21 The Mount Sinai School Of Medicine Of The City University Of New York Assays for diagnosis of thrombophilic disease
US5932712A (en) * 1997-07-31 1999-08-03 Incyte Pharmaceuticals, Inc. Annexin binding protein
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
WO2001066124A2 (en) * 2000-03-10 2001-09-13 Medinnova Sf Composition for the treatment of heart failure
DE60134009D1 (de) * 2000-05-05 2008-06-26 Inst Nat Sante Rech Med Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
IL135993A0 (en) * 2000-05-05 2001-05-20 Omrix Biopharmaceuticals Pharmaceutical composition for the treatment of fibrosis
ATE359807T1 (de) * 2001-02-21 2007-05-15 Surromed Inc Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
JP3806694B2 (ja) * 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents

Also Published As

Publication number Publication date
SI1755642T1 (sl) 2010-05-31
US20080044404A1 (en) 2008-02-21
CN1997385A (zh) 2007-07-11
PL1755642T3 (pl) 2010-06-30
ES2356364T3 (es) 2011-04-07
JP2012136536A (ja) 2012-07-19
WO2005099744A1 (en) 2005-10-27
EP1755642A1 (de) 2007-02-28
CN1997385B (zh) 2012-01-11
AU2005232436A1 (en) 2005-10-27
PT1755642E (pt) 2010-04-20
CA2563408C (en) 2015-08-25
AU2005232436C1 (en) 2010-08-26
AU2005232436B2 (en) 2010-03-11
DK1755642T3 (da) 2010-05-10
CY1109959T1 (el) 2014-09-10
EP1755642B1 (de) 2010-01-13
ATE454898T1 (de) 2010-01-15
CA2563408A1 (en) 2005-10-27
JP2007532617A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
DE602005018914D1 (de) Annexin zur prävention von der ruptur des plaques
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
CR20140465A (es) Proteinas de union a interleuquina-13
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
TN2012000302A1 (en) Oxyntomodulin peptide analogue
DE60221234D1 (de) Verwendung von füllstoffe als sättigungsmittel
ATE527365T1 (de) Il-15r alpha -sushi domäne als selektiver und effizienter verstärker der il-15-wirkung durch il-15rbeta/gamma , in hyperagonist il-15 ralpha sushi -il 15 fusionsproteine .
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
WO2012143364A3 (en) Cosmetic composition for use in increasing collagen synthesis in skin cells
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
UA99540C2 (ru) Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
MX2009007644A (es) Compuestos de piperidina heterociclicos sustituidos y usos de los mismos.
AR094275A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILE
EA201171084A1 (ru) Гели, образующиеся при сдвиговой деформации, и композиции, содержащие гели, образующиеся при сдвиговой деформации
PA8621401A1 (es) Tratamiento de la osteoporosis relacionada con la terapia de inhibidor de aromatasa
MX341064B (es) Variantes de la familia il-1.
ATE518546T1 (de) Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
TW200730190A (en) New combination to treat liver fibrosis
IL183481A (en) Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition